Last
Update:
December 08, 2014
Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
Pediatric data are indexed in the
pediatric section
XX International AIDS Conference
|
-
Darunavir (DRV)/r-based
Postexposure Prophylaxis (PEP) versus standard of care (SOC) – quality of
life in patients receiving PEP in a randomized study (PEPDar)
H. Jessen, T. Kümmerle, A.B. Jessen, et al
Abstract
-
Comparison of
effects of atazanavir, raltegravir, or darunavir with FTC/tenofovir on
biomarkers of systemic inflammation, macrophage and T cell activation: ACTG
A5260s
T. Kelesidis T.T.T. Tran, G.A. McComsey, et al
Abstract
-
DRIVESHAFT study:
switching from twice-daily darunavir/ritonavir (DRV/r) to once-daily DRV/r
in virologically-suppressed treatment-experienced HIV-infected patients
maintains
virologic suppression and improves antriretroviral adherence and LDL
cholesterol
G. Huhn, A. Sigman, B. Livak, et al
Abstract
-
HCV co-infection
does not compromised darunavir monotherapy efficacy in HIV-infected
patients, though induce higher immune activation profiles
O.-J. Ben-Marzouk Hidalgo, A. Torres-Cornejo, A. Gutiérrez-Valencia, et al
Abstract
-
Outcomes of Botswana´s highly treatment experienced adults on raltegravir
and darunavir containing ART regimens at Princess Marina Hospital in
Gaborone
A. Avalos, M. Haverkamp, V. Letsatsi, et al
Abstract
-
POSTER
Pharmacokinetics and 24-weeks efficacy of once daily
darunavir/ritonavir in virologic suppressed HIV-infected Thai children: a
pilot study
K.
Chokephaibulki, S. Rungmaitree
Poster
Abstract
-
POSTER
Bioequivalence of darunavir (800mg)
co-administered with cobicistat (150mg) as either a fixed-dose combination
tablet or as single agents under fasted and fed conditions in healthy v
T.N. Kakuda, T. van de Casteele, R. Petrovicm et al
Paper
Abstract
POSTER
Intelence aNd daRunavir Once a Day Study (INROADS): a multicenter, single-arm,
open-label study of once daily combination of etravirine (ETR) and
darunavir/ritonavir (DRV/r) as dual therapy in early treatment-expe
P. Ruane, C. Brinson, P. Kumar, et al
Poster
Abstract
Randomised
study to evaluate lopinavir/ritonavir vs. darunavir/ritonavir monotherapies as
simplification of triple therapy regimens
J.R. Santos, J. Moltó, J.M. Llibre, et al
Abstract
Changes in telomere
length after three years of darunavir/ritonavir monotherapy with and without
nucleoside analogues in the MONET trial
A. Solomon, S. Tennakoon, E. Leeansyah, et al
Abstract
Safety and efficacy
of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <
6 Years: week
48 analysisof the ARIEL trial
A. Violari, R. Bologna, N. Kumarasamy, et al
Abstract
XIX International AIDS Conference
|
-
Dynamism of
cellular HIV-DNA levels and HIV-1 protease gene changes in plasma and PBMCs in
patients
receiving
boosted-Darunavir monotherapy during 96 weeks
A. Torres-Cornejo, R. Martin-Peña, O. Ben-Marzouk Hidalgo, et al
Abstract
Darunavir/r once
daily in treatment-naïve adolescents: 48-week results of the DIONE study
C. Giaquinto, P. Flynn, S. Blanche, et al
Abstract
Outcomes of
third-line antiretroviral therapy containing darunavir, etravirine or
raltegravir in Thai children with HIV infection
J. Ananworanich,, W. Prasitsuebsai, P. Kosalaraksa, et al
Abstract
Horizontal
transmission of HIV-1 exhibiting resistance to four antiretroviral drug
classes, including integrase inhibitors
C. Walworth, D. Ward, L. Napolitano, et al
Abstract
Treatment
optimization in HIV-2-positive patients
P. Andrade, J. Soares, C. Caldas, et al
Abstract
Steady-state pharmacokinetic interactions of darunavir/ritonavir with
pitavastatin in healthy adult volunteers
C.Y. Yu, S.E. Campbell, C.A. Sponseller, et al
Abstract
Study of the immunomodulant effect of
darunavir and maraviroc on apoptosis of PBMC
I. Sauzullo, F. Mengoni, A. Ermocida, et al
Poster
Abstract
POSTER
Persistence of antiretroviral regimens including raltegravir, maraviroc,
darunavir and/or etravirine in clinical practice
I. Castillo Romera, N. Trovato López, S. Plata Paniagua, et al
Poster
Abstract
POSTER
An approach to the management of children failing second-line
antiretroviral therapy (ART) at the Botswana-Baylor
Children’s Clinical Centre of Excellence (COE) and decentralized ART sites in
Botswana
M. Tolle, A. Gomila, H. Jibril, et al
Poster
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
The MONET trial: week
144 analysis of efficacy of darunavir/ritonavir monotherapy versus DRV/r +
2NRTIs, for patients with HIV RNA < 50 copies/mL at baseline
J. Arribas, N. Clumeck, M. Nelson, et al
Abstract
Long-term safety of
once-daily (QD) darunavir/ritonavir (DRV/r) versus lopinavir/ritonavir (LPV/r)
in HIV-1-infected treatment-naïve patients in ARTEMIS
N. Clumeck, B.J. Barnett, P. Ive, et al
Abstract
A comparative analysis
of risk factors associated with efavirenz, darunavir/ritonavir,
lopinavir/ritonavir, atazanavir/ritonavir and renal impairment
N. Rockwood, M. Nelson, S. Mandalia, B. Gazzard
Abstract
24-week efficacy,
safety, tolerability, and pharmacokinetics (PK) of darunavir/ritonavir (DRV/r)
once daily (qd) in
treatment-naive
adolescents aged 12 to < 18 years in DIONE
P. Flynn, S. Blanche, C. Giaquinto, et al
Abstract
Virological impact of
introducing darunavir and raltegravir for multiexperienced HIV-1-infected
patients in Brazil
R. Hallal, H. Bernal, R. Kuchenbecker, et al
Abstract
Frequency of
resistance associated mutations to the third line protease inhibitors in
Mexican heavily antiretroviral-treated patients: report of a national advisory
board (CORESAR)
J. Andrade Villanueva, J.G. Sierra-Madero, J. Casillas Rodríguez, et al
Abstract
Despite different
instantaneous inhibitory potentials, boosted-atazanavir and boosted-darunavir
had similar clinical outcomes
G. Simoncini, C. Chien, J.C. Ricaurte, et al
Abstract
Dual therapy with
darunavir/ritonavir and etravirine in clinical practice: an NRTI-sparing
strategy in ART experienced patients
J.I. Bernardino, J. Vergas, M.J. Tellez, et al
Abstract
NRTI-sparing regimen
in clinical practice: the SCOLTA cohort
A. Di Biagio, P. Maggi, G. Pellicanò, et al
Abstract
Response to salvage
therapy among heavily ART experienced individuals at the Joint Clinical
Research Centre (JCRC) Kampala, Uganda
F. Ssali, J. Akao, J. Nantiba, et al
Abstract
XVIII International AIDS Conference
|
-
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of
two BOosted
protease inhibitors on LIpids and other marKers): comparison of the metabolic
effects of
darunavir/ritonavir versus atazanavir/ritonavir over 12 weeks
J. Aberg, T. Overton, S. Gupta, et al
PDF Poster
Abstract
POSTER
Drug-resistant genotyping to guide selection of etravirine, darunavir and
raltegravir in salvage
therapy for multi-drug-resistant cases improves outcomes
N. Miyazaki, S. Matsushita, T. Fujii, et al
PDF Poster
Abstract
POSTER
Duration of antiretroviral regimens including Raltegravir, Maraviroc,
Darunavir and/or Etravirine in
clinical practice
I. Castillo Romera, A. Ais Larisgoitia, V. Escudero Vilaplana, et al
PDF Poster
Abstract
Comparison of liver
toxicity in HIV/HCV coinfected and HIV monoinfected patients during 72 weeks
ART including darunavir/ritonavir
G. Morsica, G. Bianchi, S. Bagaglio, et al
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
The MONET trial 96
week analysis: darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for
patients with HIV
RNA < 50 copies/mL at baseline
A. Rieger, D. Banhegyi, W. Schmidt, et al
Abstract
Hepatic safety of
darunavir 600/100 in HCV coinfected patients with HAART experience
M.A. von Wichmann, M. Saenz-Cuesta, K. Aguirrebengoa, et al
Abstract
Effects of
once-daily (qd) versus twice-daily (bid) darunavir/ritonavir (DRV/r) on lipid
parameters
at week 48 in treatment-experienced, HIV-1-infected patients with no DRV
resistance-associated
mutations (RAMs) in the ODIN study
J. Arribas, E. Arathoon, C.R. Gonsalez, et al
Abstract
Darunavir/ritonavir
(DRV/rtv) increases rosuvastatin (RSV) concentrations but does not alter
lipid-lowering
effect in healthy volunteers
C. Fichtenbaum, D. Samineni, E. Moore, et al
Abstract
Hard rescue:
prospective study of effectiveness and safety of new drugs (Darunavir-DRV,
Etravirina-ETR,
Raltegravir-RTG and Maraviroc-MVC) in the last four years (2006-2009)
H. Azkune Galparsoro, J.A. Iribarren Loyarte, M.J. Aramburu Bengoechea
Abstract
Effect of adherence
on virological response to once-daily (qd) versus twice-daily (bid)
darunavir/ritonavir (DRV/r) in treatment-experienced, HIV-1-infected patients
with no DRV
resistance-associated mutations (RAMs): ODIN 48-week data
C. Workman, P. Benson, J. Valdez Madruga, et al
Abstract
Genotypic
resistance to darunavir, tipranavir and etravirine in patients with failure to
two or more
ARV combinations in Mexico
E. Vidal-Laurencio, L. Cabrera-Ruiz, A. Flores-Gaxiola, et al
Abstract
Low prevalence of
darunavir resistance mutations among HIV-1-infected patients exposed to
second-line protease
inhibitors in South India
S. Saravanan, M. Vidya, R. Kantor, et al
Abstract
Subgroup analysis and predictors of virologic response in
treatment-experienced HIV-1-infected
patients in the ODIN trial
P. Cahn, S. Hodder, P. Mootsikapun, et al
Abstract
12th European AIDS
Conference
|
A WEEK-IN-REVIEW FEATURED REPORT
PRESENTATION
Non-inferior efficacy shown across different
efficacy endpoints in the MONET trial of darunavir/ritonavir
monotherapy
D Ripamonti, J Arribas,
M
Nelson, et al
PowerPoint Presentation
POSTER
Non-inferior efficacy shown across different
efficacy endpoints in the MONET trial of darunavir/ritonavir
monotherapy
D Ripamonti, J Arribas,
M Nelson, et al
PDF Poster
POSTER
Comparative regimen durability and discontinuation reasons
among 3-class experienced patients in
a US clinical cohort
JH. Willig, I Aban, CR. Nevin, et al
PDF Poster
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Analysis of drug resistance during HIV RNA viraemia in the
MONET trial of darunavir/ritonavir
monotherapy
M Nelson, J Arribas, F Pulido, et al
PDF Poster
POSTER
Cost-efficacy analysis of the MONET trial using German antiretroviral drug
prices
M Stoll, A Hill, A Anceau, C Moecklinghoff
PDF Poster
POSTER
Low-level HIV RNA viraemia in the MONET trial: effects of assay variability
and inter-current infection
A Hill, MC Pineiro, J Arribas, et al
PDF Poster
POSTER
Treatment-experienced Women and Men in
GRACE(Gender, Race And Clinical Experience)
K Squires, J Currier, J Mrus, et al
PDF Poster
POSTER
Pharmacokinetic and Pharmacodynamic Analyses of
Darunavir in Treatment-experienced Women and
Men in GRACE (Gender, Race And Clinical Experience)
V Sekar, P Vis, B Coate, et al
PDF Poster
PRESENTATION
A Phase II, open-label trial in treatment-naïve,
HIV-1-infected patients who received DRV/r as induction
monotherapy
P Patterson, A Krolewiecki, F Tomaka, et al
PowerPoint Presentation
POSTER
Comparison of gastrointestinal adverse events of
darunavir/ritonavir and lopinavir/ritonavir at Week 96 in
ARTEMIS
J Flamm, B Rodwick, P Ive, et al
PDF Poster
POSTER
ARTEMIS 96-week comparison of liver tolerability
of once-daily darunavir/ritonavir versus lopinavir/ritonavir
in treatment-naïve patients
G Fätkenheuer, M Kelly, E Van Wijngaerden, et al
PDF Poster
|
-
A WEEK-IN-REVIEW-FEATURED REPORT
CONFERENCE PDF POSTER
GRACE (Gender,
Race And Clinical Experience): 48-week results of
darunavir/r-based therapy in the largest trial in North America focused on
treatment-experienced women
K. Squires, J. Currier, D. Bridge, et al
-
CONFERENCE POSTER
ARTEMIS: week 96 safety and efficacy of darunavir/r by gender, age and race
J. Fourie, J. Flamm, A. Rodriguez-French, et al
PDF Poster
Abstract
-
CONFERENCE POSTER
Gender analysis of darunavir in combination with low-dose ritonavir (600/100 mg
bid): results at 4
8 weeks from 79 Italian centers participating to the Expanded Access Program (EAP)
TMC114-C226
R. Termini, A. Castagna, F. Gatti, et al
PDF Poster
Abstract
-
CONFERENCE POSTER
Prevalence of darunavir resistance mutations in multi-experienced HIV-1
infected patients failing
other protease inhibitors in a developing country with free access to highly
active antiretroviral
therapy and genotyping
J.E. Vidal, A.C. Freitas A.V. Hernandez
PDF Poster
Abstract
-
CONFERENCE POSTER
Genotypic, phenotypic and virtual phenotypic
resistance patterns for tipranavir (TPV)
and darunavir (DRV): an independent analysis of a Quebec HIV-1 cohort highly
resistant
to all other protease inhibitors
A. Talbot, P. Grant, J. Taylor,
et al
PDF Poster
Abstract
-
Efficacy of
darunavir/ritonavir as single-drug maintenance therapy in patients with
HIV-1 viral
suppression: a
randomized open-label non-inferiority trial, MONOI-ANRS 136
C. Katlama, M.A. Valentin, M. Algarte-Genin, et al
Abstract
-
Agreement
degree between two genotype interpretation systems, tipranavir (TPV) and
darunavir
(DRV) validated
weighted scores (WS) and Stanford HIVdb program
M.J. Pérez Elías, C. Gutierrez, J.L. Casado
Abstract
-
Effects of
once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid
parameters and
anthropometrics in treatment-naïve HIV-1-infected ARTEMIS patients at week
96
E. Baraldi, J. Morales-Ramírez, S. Schneider, et al
Abstract
-
Darunavir/ritonavir once daily: a single centre cohort experience
C. Scott, J. Dunning, A. Teague, et al
Abstract
-
The MONET trial:
darunavir/ritonavir monotherapy shows non-inferior efficacy to standard
HAART,
for patients with HIV RNA < 50 copies/mL at baseline
J. Arribas, A. Horban, J. Gerstoft, et al
Abstract
-
48-week lipid-
and glucose-related safety profile of darunavir/ritonavir in
treatment-experienced,
paediatric
patients in DELPHI
T. Meyers, E. Joao, J.H. Pilotto, et al
Abstract
-
Recovery of
functional immunity over 48 weeks with darunavir-based therapy in the GRACE
immunology substudy
C. Tsoukas, L. Gilbert, T. Lewis, et al
Abstract
|
XVII International AIDS Conference
|
|
Darunavir Main Page
Main
New/Newsworthy
